PH12023553123A1 - Anti-nkg2a antibodies and compositions - Google Patents

Anti-nkg2a antibodies and compositions

Info

Publication number
PH12023553123A1
PH12023553123A1 PH1/2023/553123A PH12023553123A PH12023553123A1 PH 12023553123 A1 PH12023553123 A1 PH 12023553123A1 PH 12023553123 A PH12023553123 A PH 12023553123A PH 12023553123 A1 PH12023553123 A1 PH 12023553123A1
Authority
PH
Philippines
Prior art keywords
compositions
nkg2a antibodies
nkg2a
antibodies
patient
Prior art date
Application number
PH1/2023/553123A
Other languages
English (en)
Inventor
Nikolaj Dietrich
Michael Monrad Grandal
Randi Westh Hansen
Franziska Katharina Uhlenbrock
Anne Worsaae
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of PH12023553123A1 publication Critical patent/PH12023553123A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PH1/2023/553123A 2021-06-01 2022-05-31 Anti-nkg2a antibodies and compositions PH12023553123A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163195470P 2021-06-01 2021-06-01
PCT/EP2022/064703 WO2022253805A1 (en) 2021-06-01 2022-05-31 Anti-nkg2a antibodies and compositions

Publications (1)

Publication Number Publication Date
PH12023553123A1 true PH12023553123A1 (en) 2024-03-04

Family

ID=82117230

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2023/553123A PH12023553123A1 (en) 2021-06-01 2022-05-31 Anti-nkg2a antibodies and compositions

Country Status (17)

Country Link
US (2) US12012450B2 (https=)
EP (1) EP4347651A1 (https=)
JP (1) JP2024520577A (https=)
KR (1) KR20240016991A (https=)
CN (1) CN117460748A (https=)
AR (1) AR126001A1 (https=)
AU (1) AU2022286617A1 (https=)
BR (1) BR112023024772A2 (https=)
CA (1) CA3222040A1 (https=)
CL (1) CL2023003562A1 (https=)
CO (1) CO2023015982A2 (https=)
IL (1) IL308695A (https=)
MX (1) MX2023014320A (https=)
PE (1) PE20240372A1 (https=)
PH (1) PH12023553123A1 (https=)
TW (1) TW202313683A (https=)
WO (1) WO2022253805A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024140820A1 (zh) * 2022-12-28 2024-07-04 浙江博锐生物制药有限公司 抗nkg2a抗体及其用途
WO2024260280A1 (en) * 2023-06-21 2024-12-26 Elpiscience (Suzhou) Biopharma, Ltd. Antibodies or antigen-binding fragments binding to nkg2a and uses thereof
CN121941711A (zh) * 2024-02-08 2026-04-28 翰思艾泰生物医药科技(武汉)股份有限公司 Nkg2a/cd94靶向抗体及其用途
CN121108342B (zh) * 2025-09-08 2026-03-03 北京明璨生物科技有限公司 包含抗体和nk细胞的组合物在治疗癌症中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
KR20100110864A (ko) * 2008-01-24 2010-10-13 노보 노르디스크 에이/에스 인간화된 항-인간 ｎｋｇ2ａ 모노클로날 항체
SG10202007781TA (en) 2014-09-16 2020-09-29 Innate Pharma Treatment Regimens Using Anti-NKG2A Antibodies
US10329348B2 (en) * 2014-10-23 2019-06-25 Innate Pharma Treatment of cancers using anti-NKG2A agents
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
PH12018502112B1 (en) 2016-04-12 2024-03-27 Servier Lab Anti-tim-3 antibodies and compositions
US12534526B2 (en) 2018-11-07 2026-01-27 Shanghai Hyamab Biotech Co., Ltd. NKG2A antibody, preparation method therefor and application thereof
CN113316590B (zh) * 2018-11-16 2025-02-28 百时美施贵宝公司 抗nkg2a抗体及其用途

Also Published As

Publication number Publication date
US20220389100A1 (en) 2022-12-08
TW202313683A (zh) 2023-04-01
US12012450B2 (en) 2024-06-18
CN117460748A (zh) 2024-01-26
AU2022286617A1 (en) 2023-12-21
CO2023015982A2 (es) 2024-01-15
PE20240372A1 (es) 2024-03-05
EP4347651A1 (en) 2024-04-10
AR126001A1 (es) 2023-08-30
CA3222040A1 (en) 2022-12-08
WO2022253805A1 (en) 2022-12-08
JP2024520577A (ja) 2024-05-24
KR20240016991A (ko) 2024-02-06
BR112023024772A2 (pt) 2024-02-15
MX2023014320A (es) 2023-12-13
IL308695A (en) 2024-01-01
CL2023003562A1 (es) 2024-07-12
US20240294638A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
PH12023553123A1 (en) Anti-nkg2a antibodies and compositions
MX2023008193A (es) Procedimientos para tratar el cáncer.
PH12022552710A1 (en) Anti-flt3 antibodies and compositions
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
MX2022003005A (es) Composiciones y metodos de anticuerpos anti-cd39.
PH12022550509A1 (en) Anti-cd73 antibodies
PH12018502112B1 (en) Anti-tim-3 antibodies and compositions
MX2018003936A (es) Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones.
MX2023007840A (es) Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
MX2024005392A (es) Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3.
PH12022551036A1 (en) Anti-mesothelin eribulin antibody-drug conjugates and methods of use
MX2022010306A (es) Epitopos y anticuerpos del homologo del oncogen viral del sarcoma de la rata kirsten (kras).
MX2023004280A (es) Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea.
NZ754676A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
MX2023001143A (es) Anticuerpos anti-cd228 y conjugados de anticuerpos-farmacos.
MX2022010161A (es) Proteínas biespecíficas anti-her2 diseñadas.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2023008701A (es) Quinolinas y azaquinolinas como inhibidores de cumulo de diferenciacion 38 (cd38).
MX2022005238A (es) Tratamiento del cancer usando un anticuerpo biespecifico contra hla-a2/wt1 x cd3 y lenalidomida.
MX2021011040A (es) Anticuerpos dirigidos contra c5ar.
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof
MY209381A (en) Anti-axl antibodies and compositions
PH12022551021A1 (en) Sequential anti-cd19 therapy
ZA202205813B (en) Trpv1 epitopes and antibodies
MX2022011027A (es) Composiciones y metodos para el tratamiento del cancer.